First patient receives BCX7353 dosing in BioCryst ’s Phase II trial for HAE

US-based BioCryst Pharmaceuticals has started dosing patients in the Phase II ZENITH-1 exploratory clinical trial of BCX7353 to treat patients with hereditary angioedema (HAE).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news